• 대한한방부인과학회지
• /
• 제34권2호
• /
• pp.124-141
• /
• 2021

Objectives: The purpose of this study is to assess the efficacy of Jibaekjihwang-hwan and Daeboeum-hwan combination therapy for the treatment of precocious puberty. Methods: 6 databases were searched from the date of inception until April 2021 for relevant studies. We included randomized controlled trials (RCTs) and non-randomized controlled trials (nRCTs) which focused on effects of Jibaekjihwang-hwan and Daeboeum-hwan on precocious puberty. Results: Total 8 literatures were included in qualitative analysis and meta analysis on results was conducted on 4 synthesizable studies. The response rate was significantly higher in Jibaekjihwang-hwan and Daeboeum-hwan combination group than in conventional therapy group. Also, serum estradiol and follicle stimulating hormone (FSH) level were significantly lower in Jibaekjihwang-hwan and Daeboeum-hwan combination group than in conventional therapy group. Conclusions: It seems that combination therapy of Jibaekjihwang-hwan and Daeboeum-hwan can effectively reduce serum estradiol and FSH level while increasing response rate significantly. Further high quality studies are needed to supplement the efficacy and safety of combination therapy of Jibaekjihwang-hwan and Daeboeum-hwan on precocious puberty.

• 동서간호학연구지
• /
• 제29권2호
• /
• pp.161-171
• /
• 2023

Purpose: The purpose of this study is to verify the effectiveness of the Environmental Hazards Exposure Prevention Program for Mothers with Young Child (EHEPP-MYC) and to provide basic data for environmental health projects in the community. Methods: EHEPP-MYC was developed based on the protection motivation theory. A quasi-experimental design was applied to evaluate the effectiveness of the program. The number of study participants was 30 in the experimental group and 31 in the control group. The intervention applied to the experimental group consisted of lectures as the main method, current affairs programs, discussions, booklets, animations, and practical training. The program was held twice a week for a total of 4 sessions of 60 minutes each. The effect of applying the program was measured three times through surveys (before, immediately after, and two weeks after the intervention) and analyzed through repeated measures ANOVA. Results: The EHEPP-MYC had significant effects on preventive behavior, perceived severity, perceived vulnerability, self-efficacy, response efficacy, and response costs at three time points. Conclusion: EHEPP-MYC has been shown to be effective in promoting environmental hazards prevention behaviors among mothers of young child. EHEPP-MYC can be used as baseline data for projects developing programs to prevent exposure to environmental hazards and improve the environmental health of communities.

• 디지털융복합연구
• /
• 제14권5호
• /
• pp.237-245
• /
• 2016

최근 급격한 경영환경 변화로 인해 근로자들의 고용불안감이 커짐에 따라 모든 근로자들이 느끼는 직무에 대한 심리적인 불안정성은 더욱 증가하고 있는 추세에 있다. 따라서 본 연구에서는 직무불안정성과 조직시민행동간 자기효능감의 조절효과에 대하여 살펴보았다. 대상은 대전시, 세종시, 충청남 북도 소재 중소 제조업의 종업원들을 대상으로 하였으며, 2015년 8월 5일부터 동년 동월 30일까지 총 500부를 배포하여 321부가 회수되어 응답률이 64.2%였다. 회수된 설문지 중 응답이 불성실한 설문지 9부를 제외한 312부를 분석에 이용하였다. 연구결과는 다음과 같다. 첫째, 직무불안정성이 조직시민행동에 부(-)의 영향을 미치는 것으로 나타났다. 둘째, 고용불안정성과 조직시민 행동과의 관계에서 자기효능감이 조절효과가 있는 것으로 나타났다. 따라서 직무불안정성의 위협 속에서도 종업원의 자기효능감이 높으면 조직시민행동을 높일 수 있음을 의미한다. 결과적으로, 기업의 생존과 직무가 불안정한 현 상황에서 중소제조업의 경영자는 우선 종업원들에 대한 교육과 내적 보상 등을 통해 자기효능감을 높일 필요가 있다는 것을 시사한다고 할 수 있다. 연구의 한계점은 연구대상이 대전시, 세종시와 중청남 북도지역의 중소기업의 구성원들을 주된 연구표본으로 삼고 있다는 점이다. 따라서 상황적 특이성이 관찰 될 수 있기 때문에 향후에는 보다 다양한 지역, 다양한 업무 및 산업으로 확장된 연구가 필요할 것이다.

• 생물정신의학
• /
• 제6권1호
• /
• pp.96-101
• /
• 1999

Background : Since dysthymia begins in late childhood or adolescence and has a chronic course, long-term pharmacotherapy may be required. New generation antidepressant, moclobemide, with more acceptable side effect profiles, is effective in the treatment of dysthymia. The main objective of this study was to determine whether they exhibit comparable efficacy and tolerability in dysthymia to amitriptyline. Method and Materials : The efficacy and tolerability of the moclobemide and amitriptyline, were compared in a eight-week single-centre double-blind study in patients(n=37) with dysthymia using he HAMD-17, the Clinical Global Impression Scale(CGI), the Montgomery-Asberg Depression Rating Scale (MADRS), Efficacy Index-Therapeutic Index(EITE), 4-point Index Side Effect Scale(4-PISES), and Efficacy Index- Side Effect Scale(EISE). Results : A total of 37 patients entered the study, 19 were randomly assigned to the moclobemide group and 18 to be amitriptyline group. Demo-graphic and illness characteristics were similar in both groups. There were no significant difference between two groups at the total 17-HDRS score, the HAMD-17% improvement, the total MADRS score, CGI response, and the EITE. In the comparison of EISE between two groups, the scores of the moclobemide group were relatively lower than the amitriptylinen group in full treatment. And the differences were significant(moclobemide group $1.39{\pm}0.61$ ; amitriptyline group $2.00{\pm}0.85$, p<.001). At the 4-PISE, There was no serious or treatment threatening side effects. And there was no specific difference in side effects between two groups. The moclobemide group reported higher EIR scores than the amitriptyline group at every follow up day, but the differences were not significant. And, there was no significant differences in the scores of five HRQOL subcategories which is compared between two groups at every follow up days. Conclusions : In terms of 17-HDRS and MADRS, moclobemide and amitriptyline are equally effective at least in allevating dysthymic symptoms. But moclobemide tended to be less troubling and better tolerated than amitriptyline. Therefore, moclobemide treatment can be used as a safe, and higher satisfactory treatment strategy for the dysthymia.

• 실천공학교육논문지
• /
• 제16권4호
• /
• pp.471-479
• /
• 2024

본 연구는 ChatGPT를 활용한 성찰적 글쓰기 수업을 진행하였을 때 대학생의 쓰기 효능감에 인지, 정의적으로 어떠한 변화가 일어나는 가에 대해 살펴보고자 한다. 경기도 소재 S 대학교에서 교양 필수 글쓰기 교과목을 수강하는 대학생을 대상으로 ChatGPT를 활용한 성찰적 글쓰기 수업을 설계하여 5주동안 10차시에 걸쳐 진행하면서 학생들이 작성한 성찰일지를 면밀하게 검토하였고, 부가적으로 ChatGPT를 활용하기 전과 후에 측정한 쓰기 효능감 사전·사후 설문지를 통계 분석하였다. 질적자료를 분석한 결과, ChatGPT를 활용한 성찰적 글쓰기 수업이 학습자의 쓰기 효능감에 긍정적인 영향을 주었음이 확인되었다. 참여자들은 ChatGPT를 활용하면서 흥미와 더 나은 글을 쓸 수 있다는 자신감을 보였으며, 개요 짜기, 단락구성의 측면에서 ChatGPT로 생성된 샘플들을 통해 글쓰기와 관련된 지식·기능의 인지적 도움을 받고, 표절 문제에 대한 명백한 인식을 하였다. 쓰기 효능감의 설문조사 결과에서는 인지, 정의 영역의 모든 항목에서 평균의 상승을 보였으나 통계적으로 유의미한 변화를 보인 것은 '표절 대응' 항목이었다. ChatGPT로 생성된 글의 샘플들을 자기화 하는 과정은 꾸준한 연습이 필요하며, 이를 효율적으로 도와주는 유용한 도구 사용에 대한 체계적 지침이 보강되어야 할 것을 향후 과제로 제언한다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권3호
• /
• pp.1313-1320
• /
• 2014

Introduction: Although most prostate cancers initially respond to castration with luteinizing hormonereleasing analogues or bilateral orchiectomy, progression eventually occurs. Based on the exciting results of several randomized controlled trials (RCTs), it seems that patients with metastatic castration-resistant prostate cancer (mCRPC) might benefit more from treatment withabiraterone. Therefore we conducted a systematic review to evaluate the efficacy and toxicity of abiraterone in the treatment of mCRPC. Methods: Literature was searched from Embase, PubMed, Web of Science, and Cochrane Library up to July, 2013. Quality of the study was evaluated according to the Cochrane's risk of bias of randomized controlled trial (RCT) tool, then the Grading of Recommendations Assessment, Development and Evaluation (GRADE) System was used to rate the level of evidence. Stata 12.0 was used for statistical analysis. Summary data from RCTs comparing abiraterone plus prednisone versus placebo plus prednisone for mCRPC were meta-analyzed. Pooled hazard ratios (HRs) for overall survival (OS), radiographic progression-free survival (RPFS) and time to PSA progression (TTPP); Pooled risk ratios (RR) for PSA response rate, objective response rate and adverse event were calculated. Results: Ten trials were included in the systematic review; Data of 2,283 patients (1,343 abiraterone; 940 placebo) from two phase 3 trials: COU-AA-301 and COU-AA-302 were meta-analyzed. Compared with placebo, abiraterone significantly prolonged OS (HR, 0.74; 95% confidence interval [CI], 0.66 to 0.84), RPFS (HR, 0.59; 95% CI, 0.48 to 0.74) and time to PSA progression (HR, 0.55; 95% CI, 0.43 to 0.70); it also significantly increased PSA response rate (RR, 3.63; 95% CI, 1.72 to 7.65) and objective response rate (RR, 3.05; 95% CI, 1.51 to 6.15). This meta-analysis suggested that the adverse events caused by abiraterone are acceptable and can be controlled. Conclutios: Abiraterone significantly prolonged OS, RPFS and time to progression patients with mCRPC, regardless of prior chemotherapy or whether chemotherapy-na$\ddot{i}$ve, and no unexpected toxicity was evident. Abiraterone can serve as a new standard therapy for mCRPC.

• Tuberculosis and Respiratory Diseases
• /
• 제73권6호
• /
• pp.303-311
• /
• 2012

Background: This study was designed to analyze the efficacy of gefitinib as a second-line therapy, according to the clinical characteristics in Korean patients with non-small-cell lung cancer (NSCLC). Methods: In this Phase IV observational study, we recruited patients, previously failed first-line chemotherapy, who had locally advanced or metastatic NSCLC, and who were found to be either epidermal growth factor receptor (EGFR) mutation-positive or satisfied 2 or more of the 3 characteristics: adenocarcinoma, female, and non-smoker. These patients were administered with gefitinib 250 mg/day, orally. The primary endpoints were to evaluate the objective response rate (ORR) and to determine the relationship of ORRs, depending on each patient's characteristics of modified intent-to-treat population. Results: A total of 138 patients participated in this study. One subject achieved complete response, and 42 subjects achieved partial response (ORR, 31.2%). The subgroup analysis demonstrated that the ORR was significantly higher in patients with EGFR mutation-positive, compared to that of EGFR mutation-negative (45.8% vs. 14.0%, p=0.0004). In a secondary efficacy variable, the median progression-free survival (PFS) was 5.7 months (95% confidence interval, 3.9~8.4 months) and the 6-month PFS and overall survival were 49.6% and 87.9%, respectively. The most common reported adverse events were rash (34.4%), diarrhea (26.6%), pruritus (17.5%), and cough (15.6%). Conclusion: Gefitinib was observed in anti-tumor activity with favorable tolerability profile as a second-line therapy in these selected patients. When looking at EGFR mutation status, EGFR mutation-positive showed strong association with gefitinib by greater response and prolonged PFS, compared with that of EGFR mutation-negative.

• Journal of Yeungnam Medical Science
• /
• 제21권2호
• /
• pp.198-206
• /
• 2004

gemcitabine과 carboplatin으로 치료받은 경력이 있는 진행성 비소세포폐암 환자 25명을 대상으로 2차 화학요법으로 paclitaxel과 cisplatin을 사용하여 다음과 같은 결과를 확인하였다. 전체 25명 중 5명에서 부분반응이 관찰되었으며, 반응군의 반응지속기간은 2~11개월로 중앙값 4.3개월이었다. 전체 환자의 무진행생존 기간은 0~11개월로 중앙값 3.3개월이었으며, 생존기간은 1.3~39개월로 중앙값 7.4개월이었다. 전체 83회의 화학요법 중 WHO 3도의 혈소판감소증이 1회에서만 관찰되었으며, 비혈액학적 부작용도 감내할만 하였다. 이상의 결과 paclitaxel과 cisplatin 복합화학 요법은 진행서 비소세포폐암 환자에서 2차 요법으로 사용하였을 때 부작용이 적으며 효과적인 치료법의 하나로 판단된다.

• The Korean journal of internal medicine
• /
• 제39권4호
• /
• pp.577-589
• /
• 2024

Background/Aims: Four high-genetic barrier nucleos(t)ide analogues (NAs) for chronic hepatitis B (CHB), namely entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and besifovir dipivoxil maleate (BSV), have been established. The aim of this study is to investigate the efficacy of four high-genetic barrier NAs using a network meta-analysis of randomized trials and propensity score-matched cohorts. Methods: Systematic search was performed using PubMed, Cochrane library, and EMBASE and included randomized controlled trials and cohort studies that used propensity score matching. Studies on treatment-naïve CHB patients treated with ETV, TDF, TAF, or BSV were included. Outcomes included alanine aminotransferase normalization and hepatitis B e antigen seroclearance at week 48 and undetectable hepatitis B virus DNA at weeks 48 and 96. Network meta-analysis was performed to synthesize the results. Results: In total, 15,000 patients from 16 studies were included. In terms of 48- and 96-week virologic response (VR), TDF outperformed ETV with statistical significance (48 weeks: odds ratio [OR], 1.38; p < 0.001; 96 weeks: OR, 1.57; p = 0.004). ETV was ranked first for 48-week biochemical response (BR) and outperformed TDF (OR, 0.76; p = 0.028). In the sensitivity analyses, 48-week VR from randomized-controlled trials were compiled, and the same trend toward the superiority of TDF over ETV was found (OR, 1.51; p = 0.030). Conclusions: Four high-genetic barrier NAs were compared, and TDF was more likely to achieve a VR after 48 weeks, while ETV provided a superior BR after 48 weeks.

• Tuberculosis and Respiratory Diseases
• /
• 제46권2호
• /
• pp.229-240
• /
• 1999

연구배경: HSVtk/GCV를 이용한 유전자치료에서 면역반응은 1) adenovirus 혹은 retrovirus와 같이 벡타로 사용된 virus의 단백질, 2) 치료목적으로 이입된 HSVtk 유전자의 생성물, 3) 암세포에 대해서 일어날 수 있다. 그리고 이러한 면역반응은 cytokines의 생성 혹은 cytotoxic tumor-specific T-cell의 생성을 초래하여 bystander effect에 의한 살상효과를 증가시키거나, anti-tumor immunity를 유도하여 tumor vaccine의 효과를 나타낼 수 있다. 한편 이와는 대조적으로 면역반응용 HSVtk 유전자를 발현하는 세포들을 파괴하여 이입된 HSVtk 유전자의 발현기간을 제한함으로서 유전자치료의 효과를 감소시킬 수도 있다. 본 연구는 retrovirus 벡타로 이입한 HSVtk 유전자치료에서 면역체계가 bystander effect에 의한 살상효과에 미치는 영향을 규명하고 면역체계가 이입한 유전자의 발현에 미치는 영향을 조사하고자 하였다. 방 법: Immunocompetent mice인 Balb/c mouse와 immunodeficient mouse인 Balb/c-nude 및 SCID mouse에서 retrovirus 벡타를 사용하여 HSVtk 유전자를 이입하고 치료효과를 조사하였다. 그리고 Balb/c mouse에 면역억제제인 cyclosporin을 투여하여 면역억제제가 bystander effect 및 유전자치료 효과와 유전자의 발현기간에 미치는 영향을 조사하였다. 결 과: Balb/c mouse에 HSVtk 유전자를 이입하고 GCV를 투여한 군은 GCV를 투여하지 않은 대조군에 비해 종양의 성장이 유의하게 억제되었으나 Balb/c-nude mouse와 SCID mouse의 경우 GCV를 투여한 군과 대조군 사이에 유의한 차이가 없었다. 면역억제제인 cyclosporin을 투여한 군에서 유전자 치료 효과가 cyclosporin을 투여하지 않은 정상 mouse에 비해 치료효과가 유의하게 작았다. Cyclosporin 투여에 따른 유전자의 발현기간에는 유의한 차이가 없었다. 결 론: Retrovirus 벡타를 사용한 HSVtk 유전자치료에는 면역증강이 치료효과를 증가시킬 것으로 생각된다.